Xoten CA 75mg/10mg/75mg Capsule is a combination pharmaceutical formulation containing Aspirin (75mg), Rosuvastatin (10mg), and Clopidogrel (75mg), designed for the management and prevention of cardiovascular diseases. Aspirin, an antiplatelet agent, irreversibly inhibits cyclooxygenase-1 (COX-1), thereby reducing thromboxane A2 production and platelet aggregation, which helps prevent arterial thrombosis. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels, contributing to the reduction of atherosclerotic plaque progression. Clopidogrel, another antiplatelet agent, selectively inhibits the ADP P2Y12 receptor on platelet cell membranes, preventing platelet activation and aggregation, further reducing the risk of thrombotic events. This fixed-dose combination is primarily indicated for patients at high risk of cardiovascular events, including those with a history of myocardial infarction, stroke, or established peripheral arterial disease, to provide comprehensive lipid-lowering and antithrombotic effects. The use of Xoten CA should be under strict medical supervision, considering potential contraindications such as active bleeding, hypersensitivity to any component, or severe hepatic impairment. Regular monitoring of liver function, lipid profile, and bleeding parameters is recommended to ensure safety and therapeutic efficacy.